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Summary 
Vaccination  and infection can  elicit protective  and nonprotective antibodies  to  the  fungus 
Cryptococcus neoformans in mice. The effect of nonprotective antibodies on host defense is un- 
known. In this study we used mixtures of protective and nonprotective monoclonal antibodies 
(mAbs) to determine ifnonprotective mAbs blocked the activity of the protective mAbs. Anti- 
body isotype and epitope specificity are important in determining the ability to prolong survival 
in mice given a lethal C.  neoformans infection. Three different nonprotective immunoglobulin 
(Ig) G3 mAbs to cryptococcal capsular polysaccharide were used to study the interaction be- 
tween the IgG3 isotype and protective IgG1  and IgG2a mAbs in murine cryptococcal infec- 
tion. One IgG3 mAb reduced the protective efficacy of an IgG1 with identical epitope speci- 
ficity. A  second  IgG3  mAb  with  different epitope  specificity also  reduced  the  protection 
provided by the IgG1 mAb. The protective efficacy of an IgG2a mAb was also dramatically de- 
creased by still another IgG3 mAb. To our knowledge this is the first report of blocking anti- 
bodies to a fungal pathogen. The results have important implications for the development of 
vaccines and passive antibody therapy against C. neoformans. 
T 
he role of antibody immunity in resistance  to particu- 
lar pathogens is frequently determined by correlating 
the presence of specific  antibody with resistance  to infec- 
tion.  However,  the  polyclonal antibody response  that is 
elicited by  both  vaccination  and  infection  consists  of a 
complex mixture of antibodies differing in isotype, epitope 
specificity, and protective  efficacy. The  interpretation  of 
experiments using polyclonal preparations is further com- 
plicated by the fact that nonprotective antibodies have been 
shown  to  block  the  activity of protective  antibodies  in 
some bacterial infections (1-4).  Blocking activity may be 
due to direct competition for the binding of the same or 
closely related epitopes (1, 5) or to the enhancement of in- 
fection by nonprotective antibodies  through  a  variety of 
mechanisms (2,  6). This suggests that the relative amounts 
of protective and nonprotective antibodies elicited by in- 
fection or immunization can determine the outcome of in- 
fection. Passive administration of mAbs individually and in 
combination can reveal the impact of nonprotective anti- 
bodies on the polyclonal response. 
Although it is generally accepted that antibodies contrib- 
ute to resistance  to viruses and bacteria, the role ofantibod- 
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ies in fungal infections is controversial and poorly under- 
stood (7). Many of the studies supporting or contradicting 
antibody efficacy against  medically important fungi based 
their conclusions on  data obtained using polyclonal sera. 
The amount of specific antibody, the isotype composition, 
and the epitope specificity of the specific antibodies in the 
polyclonal preparations  used  in  these  studies  varied  and 
may not have been sufficient to mediate protection. When 
mAbs were used, protective and nonprotective antibodies 
were identified to Cryptococcus neoformans and Candida  albi- 
cans (7, 8). 
The difficulty in treating cryptococcal infections has re- 
newed interest in the therapeutic potential of antibody im- 
munity. C. neoformans causes a life-threatening meningoen- 
cephalitis  in  6-8%  of patients with AIDS  that is  usually 
incurable despite antifungal therapy (9). The large polysac- 
charide capsule  surrounding C.  neoformans distinguishes it 
from other fungal pathogens and is a major determinant of 
virulence (10-13). Although protective antibodies could be 
useful  therapeutically,  nonprotective  (14) and  even  en- 
hancing  (15) mAbs  to  cryptococcus have  also  been  de- 
scribed, raising the possibility that such antibodies could in- 
terfere with the  efficacy of the protective antibodies and 
increase susceptibility to infection. In this study we tested 
the impact of nonprotective IgG3 mAbs on the ability of 
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coccal  infection  in  the  mouse.  Our  results  indicate  that 
rather  than  being  simply ineffective,  IgG3  antibodies re- 
duce the protection provided by the IgG1  and IgG2a iso- 
types. 
Materials and Methods 
C. neoformans.  C,  neoformans strain 24067  (serotype D)  was 
obtained from  the  American Type  Culture  Collection (R.ock- 
ville, MD)  and  maintained on  Sabouraud  dextrose agar  (Difco 
Laboratories Inc., Detroit, MI) slants at 4~  For mouse infection, 
C.  neoformans was grown at 37~  in Sabouraud dextrose broth 
(Difco Laboratories Inc.). Yeast cells were washed three times in 
PBS, and the inoculum was determined by counting in a hemocy- 
tometer. 
mAbs.  The IgG3 mAb 3E5 was generated in response to im- 
munization  with  glucuronoxylomannan  (GXM)  conjugated  to 
tetanus toxoid (16).  3E5 IgG1 was generated by in vitro isotype 
switching (15). 4H3 IgG3 was generated in response to infection 
with C.  neoformans strain GH (16).  A2F12 IgG3 and 7F8 IgG2a 
were generated from NZB/W F1 mice in response to immuniza- 
tion with GXM cross-linked to Pseudomonas aemginosa exoprotein 
A (GXM-PsA) (Nussbaum, G., A. Casadevall, and M.D. Scharff, 
manuscript in preparation). All mAbs bind to serotype D  capsular 
GXM. 
Ascites Preparation.  Ascites was generated by injecting 10  7 hy- 
bridoma cells into the peritoneal cavity ofpristane-primed BALB/c 
mice. Antibody concentration was determined by ELISA relative 
to isotype-matched standards of known concentration. Although 
4H3 is an IgG3h mAb, the 4H3 hybridoma produces a small per- 
centage of antibody with K light chains (17), and the K chain con- 
taining  antibodies was  removed by  absorbing the  ascites  three 
times on a rat anti-mouse K Sepharose 4B column (Zymed Labo- 
ratories Inc., South San Francisco, CA). 
Animal Experiments.  Female A/J mice ages 6-8 wk were used 
for protection experiments. Mice were  obtained from the Na- 
tional Cancer Institute (Rockville, MD) for the intravenous in- 
fection experiments and from The Jackson Laboratory (Bar Har- 
bor, ME) for the intraperitoneal experiment, based on availability. 
A/J mice were chosen because they are highly susceptible to in- 
fection  with  C.  neoformans (18).  Protection  experiments  were 
performed as described (19,  20).  C.  neoformans was administered 
intravenously through the tail vein or by intraperitoneal injection. 
mAb was administered intraperitoneally either 24 h before infec- 
tion in the case of intravenous challenge, or ~30 min before in- 
fection in the case of intraperitoneal challenge. The dose of each 
mAb was 1 mg. Animals who received two antibodies received a 
total of 2 mg mAb mixed before challenge. The cryptococcal in- 
oculum was 2 ￿  106 cells/mouse in the case of intravenous infec- 
tion and 108 cells/mouse in the case of intraperitoneal infection. 
Deaths were recorded daily. 
Statistics.  Survival data were analyzed by the Mann-Whitney 
test  using  statistical  software  for  the  Macintosh  (Instat version 
2.01;  GraphPAD Software for Science, San Diego, CA). 
Results 
Effect of IgG3  on a Protective IgG1  with Identical Specifidty. 
In previous studies, we demonstrated that 3E5  IgG3 mAb 
did not protect mice from lethal infection with  C.  neofor- 
mans  (15,  19). When 3E5  IgG3 was switched to the IgG1 
isotype,  it  prolonged  survival  and  reduced  tissue  fungal 
burden (15). mAb 3E5  IgG3 and its 3E5  IgG1 switch vari- 
ant have identical variable regions but differ in isotype (15). 
To  determine  the  effect  of 3E5  IgGl  and  3E5  IgG3  in 
combination, 1 mg of each antibody was given alone or in 
combination  to  groups  of five  mice  24  h  before intrave- 
nous  infection with 2  ￿  106  cryptococci. Consistent with 
previous  results  (15),  3E5  IgG3  did  not  prolong  survival 
compared  with  saline  controls  (P  =  0.249),  whereas  the 
IgG1 switch variant did (P =  0.0002,  Fig. 1). Mice who re- 
ceived  1  mg each  of IgG1  and  IgG3 were  still protected 
compared with the PBS control group  (P =  0.0085);  how- 
ever,  protection was  significantly reduced  compared with 
mice receiving the IgG1 alone (P =  0.0052).  Thus,  admin- 
istration of IgG3 reduced the protective efficacy of an IgG1 
with identical epitope specificity in mice infected intrave- 
nously with C. neoformans. 
Effea of IgG3  on a Proteaive  lgGl  with Different  Specificity. 
4H3  is a nonprotective IgG3k mAb generated in response 
to  infection with  C.  neoformans  strain  GH  (16).  4H3  and 
3E5  use different but related H  chain variable region genes 
(VH441/JH3  and  V.7183/JH2,  respectively),  different  L 
chain variable region genes  (Vxl  and Vk5.1,  respectively), 
bind different epitopes on cryptococcal polysaccharide (16), 
and do not compete by ELISA (our unpublished observa- 
tions).  Administration of 4H3  IgG3  did not  protect mice 
from intravenous infection and reduced survival compared 
with  the control mice  (P =  0.0079,  Fig. 2).  As expected, 
3E5  IgG1 prolonged survival (P =  0.0079).  Mice who re- 
ceived a mixture of I  nag each of4H3  IgG3 and 3E5 IgG1 
were neither protected nor was infection enhanced relative 
to saline controls (P =  0.4206).  Administration of the mix- 
ture  resulted in  a  significantly shorter  mean  survival than 
administration  of 3E5  IgG1  alone  (P  =  0.0317)  and  a 
longer  survival  than  treatment  with  4H3  alone  (P  = 
0.0079).  Thus,  an IgG3 mAb with different epitope speci- 
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Figure 1.  lgG3 blocks protective IgGl with identical specificity. Sur- 
vival curves of A/J mice given either mAb or PBS (control) show the ef- 
fect of lgG3  mAb  (3E5 IgG3) administration on an  IgG1 mAb  (3E5 
IgG1) with identical epitope specificity. 1 mg of each antibody was given 
alone or in combination intraperitoneally 24 h before intravenous chal- 
lenge with 2 ￿  106 C. neoformans. Average survival  and standard deviation 
for the lgG1, IgG3, IgG1 + IgG3 combination, and PBS groups (n t>11/ 
group) were 20.55 •  4.78, 9.17 •  2.86, 14.64 •  2.73, and  10.91  • 
2.47 d, respectively. 
1906  Blocking Antibodies to Cryptococcus neoformans 100 
8O 
N  40 
20 
m 
I 
1  2  3  4  "~  6  7  8  14 
Days After Infection 
￿9  3E5 IgG1 
O 4H3 IgG3 
9  10  11  12  ~'3 
Figure 2.  IgG3 blocks protective IgG1 with different specificity. Sur- 
vival curves of  A/J mice given either mAb or PBS (control) show the ef- 
fect of lgG3 mAb (4H3) administration on an IgGl mAb (3E5 IgG1) 
with different epitope specificity. 1 nag of each antibody was given alone 
or in  combination intraperitoneally 24 h before intravenous challenge 
with 2 ￿  106 C. neoformans. Average survival and standard deviation for 
the IgG1, IgG3, 3E5 IgG1 + 4H3 IgG3 combination, and PBS groups 
(n = 5/group) were 11,00 -+ 1.58, 4.20 + 0.84, 7.00 --+ 2.24, and 5.98 + 
0.04 d, respectively. 
ficity reduced the efficacy of an IgG1 mAb when they were 
administered  simultaneously  in routine  intravenous  infec- 
tion. 
Effect of lgG3 on a Protective IgG2a.  IgG3  mAb  A2F12 
and  IgG2a mAb 7F8  were recovered from splenic  fusions 
of different  NZB/W  mice  immunized  with  GXM-PsA 
(Nussbaum,  G., et al., manuscript in preparation).  For pro- 
tection  experiments,  groups  of mice were  given  1  mg of 
each mAb alone  or in combination before intraperitoneal 
challenge with 108 cryptococci. The IgG2a mAb 7F8 alone 
conferred significant protection (P =  0.0001, Fig. 3) and, as 
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Figure 3.  IgG3 blocks protective IgG2a. Survival curves of A/J mice 
given either mAb or PBS (control) show the effect of IgG3 mAb (A2F12) 
administration on IgG2a (7F8)-mediated protection. 1 nag of each anti- 
body was given alone or in combination intraperitoneally ~30 min be- 
fore intraperitoneal challenge with 108 C. neoformans. Average survival 
and standard deviation for the IgG2a, IgG3, lgG2a +  IgG3, and PBS 
groups (n = 10 for lgG2a and IgG3 groups, 9 for IgG2a + IgG3 group, 
and 11 for PBS group) were 111.30 +  35.77, 19.20 +  9.54, 61.00 --+ 
43.08, and 11.64 + 2.34, respectively. 
with some of our other IgG3 nLAbs, A2F12 was minimally 
protective  (P =  0.0357).  Animals who received  1 mg each 
of 7F8 and A2F12 died faster than those who received 7F8 
alone (P =  0.0172) but survived longer than the group who 
received A2F12 alone (P =  0.001).  Thus an IgG3 mAb re- 
duced the protective efficacy of an IgG2a mAb in a murine 
model ofintraperitoneal infection. 
Discussion 
Three different IgG3 mAbs to GXM were studied,  and 
all reduced the efficacy of protective GXM-binding mAbs. 
In  the  first  case,  we  used  3E5  IgG3  and  IgG1  isotype 
switch  variants  that  bind  to  the  same  epitope  (15).  The 
IgG3 was ineffectual when administered alone and reduced 
survival  provided  by  IgG1.  Since  these  antibodies  may 
compete  for binding  to  the  surface  of the  organism,  the 
nonprotective IgG3, which binds with higher avidi  W  (15) 
because  of cooperative  IgG3  Fc-Fc interactions  (21,  22), 
may block  effective  opsonization  by IgG1.  We  therefore 
tested IgG3 and IgG1 antibodies that use different H  and L 
chain variable region genes, bind different epitopes on the 
cryptococcal  capsule  (19,  23),  and  do  not  compete  by 
ELISA. In this case, the 4H3 IgG3 alone enhances crypto- 
coccal infection.  When  administered  together with  IgG1, 
4H3  IgG3  abolished  the  3E5  IgG1  mediated  protection. 
Finally,  we mixed  an  IgG3 that was minimally protective 
when given alone with a highly protective IgG2a in a dif- 
ferent  model  of infection.  These  antibodies  use  the  same 
variable  region  genes  but  have  unique  somatic  mutations 
that may or may not confer differences in fine specifici  W. 
In this experiment,  the IgG3 again reduced protection pro- 
vided by IgG2a. 
To our knowledge, this is the first report of blocking an- 
tibodies  to a fungal pathogen.  The  term  blocking antibodies 
describes nonbactericidal antibodies  that prevent killing by 
bactericidal  antibodies  or complement in  a  wide range  of 
gram-negative organisms. Antibodies that are unable to fix 
complement  effectively  or  to  promote  phagocytosis  may 
prevent protective antibodies from binding by competition 
for  the  same  epitope,  or  by  steric  hindrance  when  they 
bind to different,  but closely located,  epitopes.  For exam- 
ple,  IgG antibodies to the outer membrane protein PIII of 
Neisseria gonococcus block bactericidal antibody binding to PI 
and  fix  complement on sites  that  do  not lead  to bacterial 
death  (1,  6,  24).  Human  convalescent  gonococcal  and 
meningococcal  antisera  can  effectively  block  the  natural 
bactericidal activity of normal serum (1, 2, 5), and preexist- 
ing  antibody  to  gonococcal  PIII  facilitates  gonococcal 
transmission  (24,  25).  Human IgA1 against N.  meningitides 
blocks  IgG  bactericidal  activity  when  both  are  directed 
against distinct polysaccharide epitopes  (2).  In Dengue vi- 
rus infection,  virus-reactive  antibody enhances cel/ular in- 
fection in  vitro  (26)  and  in  vivo  (27),  and  severe  disease 
(Dengue shock syndrome and Dengue hemorrhagic fever) 
occurs most often in patients with a preexisting low level of 
IgG antibody (for review see reference 28).  Nonneutraliz- 
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against bacteria (30) in general may interfere with the biva- 
lent binding of protective antibodies and may explain why 
antibody responses to certain infections are not protective. 
Both complement fixing classes of antibody and those that 
fix complement poorly have been shown to contain block- 
ing activity. In the studies reported here, we found that the 
murine IgG3 subclass  that fixes complement and promotes 
phagocytosis in  the  presence of complement components 
(31) had blocking activity in vivo. 
Our discovery of blocking mAbs to  C.  neoformans  sug- 
gests a potential explanation for the inconsistent results ob- 
tained in protection experiments with polyclonal sera (32- 
34). IgG3 is the major IgG isotype elicited in the mouse by 
T  cell-independent  type II antigens  (35),  such  as  crypto- 
coccal  polysaccharide  (36).  In  addition,  IgG3  antibodies 
bind with  increased  avidity because of cooperative Fc-Fc 
interactions  after  antigen  binding  (21,  22).  The  fact  that 
IgG3  anticryptococcal  antibodies  are  both  nonprotective 
and able to block antibody immunity raises  the intriguing 
possibility that  these  antibodies  could promote fungal in- 
fection and that the titer of IgG3 antibodies in polyclonal 
sera may explain the variable efficacy ofpolyclonal prepara- 
tions administered passively (32,  33) or elicited by immuni- 
zation with polysaccharide-protein conjugates (34).  If anti- 
cryptococcal  antibodies  with  blocking  activity  occur  in 
humans, isotype differences between HIV-positive and HIV- 
negative individuals could contribute to increased suscepti- 
bility to cryptococcal infection (37). 
Several  mechanisms  could  explain  the  IgG3-mediated 
blocking activity. A  straightforward competition for anti- 
genic sites or a difference in antigenic density or accessibil- 
ity is unlikely to  explain this  phenomenon,  since we  ob- 
served  interference  with  antibodies  that  bind  distinct  as 
well as identical epitopes. For the 3E5 IgG3 and IgG1 pair, 
antigen  density  is  presumably  the  same  since  they  have 
identical variable regions. IgG3 antibodies may modify the 
structure  or flexibility of the  capsule,  preventing effective 
opsonization by IgG1 and IgG2a. IgG3 may facilitate pha- 
gocytosis by effector cells  that  are  not primed for killing, 
countering  the  protective  effect of lgG1  and  lgG2a.  Fi- 
nally, IgG3 immune complexes could conceivably alter the 
innate cytokine response to infection, thus suppressing cell- 
mediated immunity. 
Our  results  indicate  that  murine  IgG3  antibodies  to 
C. neoformans  GXM  are  deleterious  to  the  host by either 
enhancing  infection  or  interfering  with  the  function  of 
protective  antibodies.  In  contrast,  mAbs  of IgM,  IgG2a, 
IgG2b, and IgA isotypes have all been shown to be protec- 
tive (19,  38). The ineffectiveness oflgG3 antibodies against 
C.  neoformans contrasts with the effectiveness of this isotype 
against  other  encapsulated  pathogens  such  as  Streptococcus 
pneumoniae  (39).  Our findings have important implications 
for the potential use of antibodies in the treatment and pre- 
vention of cryptococcal infection. Human correlates of the 
murine protective and nonprotective isotypes, if they exist, 
need to be identified and this information applied to vaccine 
design and the selection of antibodies for passive therapy. 
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